Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma

Esther Drent, Richard Groen, PhD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Jurgen H Kuball, MDPhD, Zsolt Sebestyen, PhD, Niels W.C.J. van de Donk, MDPhD, Anton C. Martens, PhD, Henk M. Lokhorst, MDPhD, Tuna Mutis, MDPhD

Blood (2014) 124 (21): 4759.

https://doi.org/10.1182/blood.V124.21.4759.4759

Published: 2014

Journal Articles

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Alba Matas-Céspedes, MS, Anna Vidal-Crespo, MS, Vanina Rodriguez, Julio Delgado, MD PhD, Neus Villamor, MD PhD, Gael Roue, PhD, Elías Campo, MD PhD, Dolors Colomer, PhD, Parul Doshi, PhD, Adrian Wiestner, MD PhD, Paul W.H.I. Parren, PhD, Jeroen Lammerts van Bueren, PhD, Patricia Pérez-Galán, PhD

Blood (2014) 124 (21): 4680.

https://doi.org/10.1182/blood.V124.21.4680.4680

Published: 2014

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren, PhD, Danielle Jakobs, Niels Kaldenhoven, Marcel Roza, Sanne Hiddingh, Joyce Meesters, Marleen Voorhorst, Elke Gresnigt, Luus Wiegman, Antonio Ortiz Buijsse, Grietje Andringa, Marije B. Overdijk, PhD, Parul Doshi, PhD, Kate Sasser, Michel de Weers, PhD, Paul W.H.I. Parren, PhD

Blood (2014) 124 (21): 3474.

https://doi.org/10.1182/blood.V124.21.3474.3474

Published: 2014

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

Alba Matas-Céspedes, MS, Anna Vidal Crespo, MS, Vanina Rodriguez, Gael Roue, PhD, Armando Lopez-Guillermo, MD, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2013) 122 (21): 378.

https://doi.org/10.1182/blood.V122.21.378.378

Published: 2013

Journal Articles

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Frank J Beurskens, PhD, Rob N de Jong, PhD, Sandra Verploegen, PhD, Marleen Voorhorst, Kristin Strumane, PhD, Margaret A. Lindorfer, PhD, Ronald P. Taylor, PhD, Erica Ollmann Saphire, PhD, Dennis Burton, PhD, Janine Schuurman, PhD, Paul W.H.I. Parren, PhD

Blood (2013) 122 (21): 375.

https://doi.org/10.1182/blood.V122.21.375.375

Published: 2013

Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 277.

https://doi.org/10.1182/blood.V122.21.277.277

Published: 2013

Journal Articles

Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.

J. H. Marco Jansen, Peter Boross, PhD, Marije B. Overdijk, PhD student, Jeroen J. Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Jeanette H. W. Leusen, PhD

Blood (2012) 120 (21): 2974.

https://doi.org/10.1182/blood.V120.21.2974.2974

Published: 2012

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Alba Matas-Céspedes, BS, Anna Vidal-Crespo, BS, Vanina Rodriguez, Gael Roue, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2012) 120 (21): 3935.

https://doi.org/10.1182/blood.V120.21.3935.3935

Published: 2012

Journal Articles

Phagocytosis Is A Mechanism of Action for Daratumumab

Marije B. Overdijk, PhD student, Sandra Verploegen, PhD, Bögels Marijn, PhD student, Marjolein van Egmond, Prof., Richard W.J. Groen, PhD, Anton C.M. Martens, PhD, Jeroen Lammerts van Bueren, PhD, Wim Bleeker, PhD, Paul W.H.I. Parren, PhD

Blood (2012) 120 (21): 4054.

https://doi.org/10.1182/blood.V120.21.4054.4054

Published: 2012

Journal Articles

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 1834.

https://doi.org/10.1182/blood.V120.21.1834.1834

Published: 2012

Journal Articles

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Richard W Groen, PhD, Willy A Noort, PhD, Reinier Raymakers, MD, PhD, Henk-Jan Prins, Msc, Linda Aalders, Frans M Hofhuis, Berris van Kessel, Petra Moerer, Henk Rozemuller, PhD, Jan J. Schuringa, PhD, Joost de Bruijn, PhD, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD, Anton CM Martens, PhD

Blood (2011) 118 (21): 3412.

https://doi.org/10.1182/blood.V118.21.3412.3412

Published: 2011

Journal Articles

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G.J. van de Winkel, Paul W.H.I. Parren, PhD, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2011) 118 (21): 103.

https://doi.org/10.1182/blood.V118.21.103.103

Published: 2011

Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1865.

https://doi.org/10.1182/blood.V118.21.1865.1865

Published: 2011

Journal Articles

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2843.

https://doi.org/10.1182/blood.V116.21.2843.2843

Published: 2010

Journal Articles

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Sun-Young Kong, MD, PhD, Xian-Feng Li, Sabikun Nahar, Weihua Song, MD, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 3013.

https://doi.org/10.1182/blood.V116.21.3013.3013

Published: 2010

Journal Articles

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Pia Glorius, Anne Baerenwaldt, Christian Kellner, Matthias Staudinger, Paul W.H.I. Parren, Jan G. J. van De Winkel, Andreas Humpe, Thomas Valerius, Roland Repp, Falk Nimmerjahn, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2846.

https://doi.org/10.1182/blood.V116.21.2846.2846

Published: 2010

Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2010) 116 (21): 3058.

https://doi.org/10.1182/blood.V116.21.3058.3058

Published: 2010

Journal Articles

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Shulamiet Wittebol, Joost M Bakker, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 3059.

https://doi.org/10.1182/blood.V116.21.3059.3059

Published: 2010

NARROW

CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Phagocytosis Is A Mechanism of Action for Daratumumab

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only